<div id="readability-page-1"><div id="parent_top_div"><p>Sun Pharmaceutical has announced that its subsidiary, Taro Pharmaceuticals, has entered into an agreement to acquire a 100 per cent stake in Antibe Therapeutics, a clinical-stage biotechnology company based in Ontario, Canada.</p> <p>  The acquisition is expected to be completed before March 7, 2025, subject to approval from the Ontario Superior Court of Justice.</p> <p>  The transaction is part of Sun Pharma’s strategy to expand its pharmaceutical and healthcare portfolio, particularly in the area of pain and inflammation management. Antibe Therapeutics specialises in developing novel drugs focused on reducing pain and inflammation.</p> <p>  Founded in 2009, the company is currently under court-appointed receivership and has reported no revenue for the past three years.</p> <p>  Sun Pharma has stated that the acquisition consideration will be in cash, but the amount will not be disclosed until the transaction closes, due to court oversight of the divestiture of Antibe.</p> <p>  “Sun Pharma shall update the consideration to stock exchanges once the transaction is completed,” the company stated in an exchange filing.</p> <p>On the same day, Sun Pharma’s stock rose 0.38 per cent to Rs 1,763.50 apiece on Thursday.</p></div></div>

Taro藥業

<p>Sun Pharmaceutical 的子公司 Taro Pharmaceuticals 將收購位於加拿大安大略省的臨牀階段生物技術公司 Antibe Therapeutics 的 100% 股份。此交易旨在增強 Sun Pharma 在疼痛和炎症管理領域的產品組合，預計將在 2025 年 3 月 7 日之前完成，待法院批准。Antibe 成立於 2009 年，已處於接管狀態，並且在過去三年內沒有產生收入。此次收購將以現金方式進行，具體細節將在交易後披露。公告發布後，Sun Pharma 的股價上漲了 0.38%，達到了 1,763.50 印度盧比</p>

太陽製藥的子公司 Taro 將收購 Antibe Therapeutics 的全部股權